Rasagiline Added to Aricept in Patients With Mild to Moderate Alzheimer's Disease
- Study Title
- Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)
- Teva Identifier
- TVP-1012-A001-201
- ClinicalTrials.gov Identifier
- NCT00104273
- Study Status
- Completed
- Trial Condition(s)
- Dementia | Alzheimer's Disease
- Interventions
- Drug: Rasagiline
Study Description
Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult, Older Adult
- Age Range
- 45 Years to 90 Years
- Trial Duration
- 08/01/2004 - 01/00/1900
- Phase
- Phase 2
